Nuclear NAD+ homeostasis is essential for naive and chemoresistant BRCA1/2-deficient tumor survival
D. Musiani, H. Yucel, L. Sourd, E. Marangoni, R. Ceccaldi
This study identifies NMNAT1 as a therapeutic target for BRCA1/2-deficient tumors, showing its synthetic lethality with BRCA1/2 in a PARP1-independent but SIRT6-dependent manner.
bioRxiv · Dec 9, 2021Cancer Biology